Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is one of the most important rare disease biotechnology companies because it validated RNA interference as a therapeutic modality and built approved medicines for genetically or biologically defined diseases. Its platform is especially relevant to rare diseases where silencing a disease-causing gene can produce meaningful clinical benefit.
- Highest 2026 tier: Tier I
- Rare Disease & Orphan Drug Developers
- 3 ranking categories
Overview
Alnylam Pharmaceuticals is one of the most important rare disease biotechnology companies because it validated RNA interference as a therapeutic modality and built approved medicines for genetically or biologically defined diseases. Its platform is especially relevant to rare diseases where silencing a disease-causing gene can produce meaningful clinical benefit.
Alnylam’s strength lies in platform validation. The company converted RNAi from a scientific promise into approved therapies and a repeatable development engine. Its products and pipeline span rare genetic disease, amyloidosis, cardiometabolic disease, and other specialty indications.
Alnylam Pharmaceuticals is included in 3 2026 ranking categories. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Alnylam Pharmaceuticals |
| Founded | 2002 |
| Institution type | Rare Disease & Orphan Drug Developers institution |
| Headquarters | Cambridge, United States |
| Primary focus | Rare Disease & Orphan Drug Developers |
| Highest 2026 ranking tier | Tier I |
Principal activities
Alnylam’s strength lies in platform validation. The company converted RNAi from a scientific promise into approved therapies and a repeatable development engine. Its products and pipeline span rare genetic disease, amyloidosis, cardiometabolic disease, and other specialty indications.
Core capability
Rare Disease & Orphan Drug Developers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Rare Disease & Orphan Drug Developers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Alnylam’s RNAi platform, approved rare disease products, scientific differentiation, and long-term pipeline support its Tier I position.
Alnylam Pharmaceuticals is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Alnylam Pharmaceuticals should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Alnylam Pharmaceuticals. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Alnylam Pharmaceuticals |
| Headquarters | Cambridge, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Rare Disease & Orphan Drug Developers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Biotechnology Firms 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Specialty Pharma Companies 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
